Risk adjusted net present value: What is the current valuation of Johnson & Johnson’s Nipocalimab?

Nipocalimab is a monoclonal antibody commercialized by Johnson & Johnson, with a leading Phase III program in Acquired (Autoimmune) Hemolytic Anemia.

Merck clinches priority review for pneumococcal vaccine, raising stakes for Pfizer

The FDA on Tuesday granted Merck priority review for its investigational pneumococcal vaccine, making strides ahead of Pfizer in the companies’ yearslong contest atop the

December 20, 2023

Updated: Lilly’s shares tank after trimming revenue guidance. It also cut three assets

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

October 31, 2024

Tilray Q1 Cannabis Revenue Increases 9% Sequentially

Tilray Brands Reports Q1 2024 Financial Results Record Q1 Net Revenue of $177 Million, Representing 15% Growth Year over Year Increased #1 Cannabis Market Share

October 4, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.